A Study of BGM-2121 in Patients With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
Key facts
- Study ID
- NCT07346846
- Run by
- BioGate Precision Medicine Corp.
- People needed
- 35
- Starts
- 2026-03-10
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- With either gender aged ≥ 18 years,
- Has a confirmed diagnosis of advanced solid tumor(s),
- The subject has received and failed standard-of-care anti-cancer therapy
- Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
- ...
You may not qualify if…
- Has any ongoing toxicity from previous anti-cancer treatments
- Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
- History of another primary malignancy within the last three years
- ...
Where it is running
- Taipei Veterans General Hospital — Taipei, Taiwan (enrolling)
- National Cheng Kung University Hospital — Tainan, Taiwan
- National Taiwan University Hospital — Taipei, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.